Evidence map›Paper›PMID 21954347›Full record

ArticleInternational journal of molecular sciences2011

Combined 3D-QSAR and Docking Modelling Study on Indolocarbazole Series Compounds as Tie-2 Inhibitors.

Yuanxin Tian, Jian Xu, Zhonghuang Li, Zhengguang Zhu, Jiajie Zhang, Shuguang Wu

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Yuanxin TianSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; E-Mails: tyx523@163.com (Y.T.); woshixvjian@126.com (J.X.); lzhuang@fimmu.com (Z.L.); zzg@fimmu.com (Z.Z.); shuguang@fimmu.com (S.W.).
Jian Xu
Zhonghuang Li
Zhengguang Zhu
Jiajie Zhang
Shuguang Wu
Southern Medical University · CNHesco (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tie-2, a kind of endothelial cell tyrosine kinase receptor, is required for embryonic blood vessel development and tumor angiogenesis. Several compounds that showed potent activity toward this attractive anticancer drug target in the assay have been reported. In order to investigate the structure-activity correlation of indolocarbazole series compounds and modify them to improve their selectivity and activity, 3D-QSAR models were built using CoMFA and CoMSIA methods and molecular docking was used to check the results. Based on the common sketch align, two good QSAR models with high predictabilities (CoMFA model: q(2) = 0.823, r(2) = 0.979; CoMSIA model: q(2) = 0.804, r(2) = 0.967) were obtained and the contour maps obtained from both models were applied to identify the influence on the biological activity. Molecular docking was then used to confirm the results. Combined with the molecular docking results, the detail binding mode between the ligands and Tie-2 was elucidated, which enabled us to interpret the structure-activity relationship. These satisf actory results not only offered help to comprehend the action mechanism of indolocarbazole series compounds, but also provide new information for the design of new potent inhibitors.

Indexed as

Models, MolecularQuantitative Structure-Activity RelationshipCarbazolesHydrogen BondingHydrophobic and Hydrophilic InteractionsInhibitory Concentration 50Molecular ConformationMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingProtein Kinase InhibitorsReceptor, TIE-2CarbazolesProtein Kinase InhibitorsReceptor, TIE-23D-QSAR, CoMFACoMSIAdockingTie-2 kinase inhibitor

Identifiers

PMID21954347
PMCPMC3179154
OpenAlexW2055843168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.